D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $12 from $24 and keeps a Buy rating on the shares after the company announced it is discontinuing the development of CT-0525 as part of a “strategic reprioritization. The firm reduced HERII cancers from its projections.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics announces restructuring, 34% workforce reduction
- Carisma Therapeutics Restructures Amid Strategic Refocus
- Carisma Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)